The number of shares of common stock outstanding after the offering is based on 11,759,022 shares of common stock outstanding as of December 31, 2018 on pro forma basis consisting of (i) 10,636,473 shares of common stock outstanding as of December 31, 2018, (ii) the issuance of an aggregate of 1,072,156 shares of common stock in January and February 2019 to BioLexis pursuant to our November 2018 private placement, and (iii) the issuance of an aggregate of 50,393 shares of common stock in February and March 2019 upon conversion of an aggregate $0.5 million principal amount of our senior secured notes; and excludes, as of that date, the following:
•
16,136 shares of common stock issuable upon the exercise of outstanding performance-based stock unit awards, or PSUs, whose terms provide for settlement in shares of common stock or cash at our discretion, with a weighted-average exercise price of $49.99;
•
7,457 shares of common stock issuable upon vesting of outstanding restricted stock unit awards, or RSUs, granted under our 2015 Equity Incentive Plan, or the 2015 Plan, with a weighted-average grant date fair value of $155.28;
•
386,247 shares of common stock issuable upon exercise of outstanding stock options granted under the 2015 Plan with a weighted-average exercise price of $7.16, plus an additional 350,000 shares issuable upon exercise of stock options granted under the 2015 Plan on February 19, 2019;
•
490,767 shares of common stock reserved for future issuance under the 2015 Plan (140,767 after the reduction of 350,000 shares for stock options granted under the 2015 Plan on February 19, 2019), plus an additional 319,094 shares reserved for future issuance as of January 1, 2019, as well as any future automatic increases in the number of shares of common stock reserved for future issuance under the 2015 Plan;
•
68,145 shares of common stock reserved for future issuance under our 2016 Employee Stock Purchase Plan, or the ESPP, as well as any automatic increases in the number of shares of common stock reserved for future issuance under the ESPP;
•
5,661,015 shares of common stock issuable upon the exercise of outstanding warrants, with a weighted-average exercise price of $8.11 per share;
•
955,927 shares of common stock issuable upon the conversion of outstanding senior secured notes having an aggregate principal amount of $8.6 million as of March 19, 2019;
•
145,221 shares of common stock issuable upon conversion of outstanding principal and accrued interest on unsecured notes having an aggregate principal amount of $1.0 million as of March 19, 2019;
•
1,166,156 shares of common stock issuable upon conversion of the 61,708 outstanding shares of our Series A-1 Convertible preferred stock, as well as any future shares of common stock issuable upon conversion of additional shares of Series A-1 Convertible preferred stock that may be issued as payment-in-kind dividends thereon in accordance with their terms;
Except as otherwise indicated herein, all information in this prospectus, including the number of shares of common stock that will be outstanding after this offering, reflects:
•
a 1-for-8 reverse stock split of our common stock effected March 15, 2019;
•
the issuance of an aggregate of 1,072,156 shares of common stock in January and February 2019 to BioLexis Pte. Ltd., or BioLexis, pursuant to the November 2018 private placement;
•
the issuance of an aggregate of 50,393 shares of common stock in February and March 2019 upon conversion of an aggregate $0.5 million principal amount of senior secured notes;
•
no exercise of outstanding options or warrants, or conversion of notes, or settlement of PSUs or RSUs in shares of stock, in each case listed above; and
•
no exercise of the warrants offered hereby.